Brussels, 28/09/2006 (Agence Europe) - The attempt by laboratories - British group Glaxo (GSK) and more recently Pfizer of the United States - to limit parallel trade in medicines on the internal market must go no further, even though the Commission feels it is being criticised for failing to examine adequately the request for an exemption submitted to it. In a ruling delivered in Luxemburg on Wednesday, the Court of First Instance, to the great satisfaction of the parallel distributors of...